Reaction
Immune-Mediated Pancreatitis reporting signals
As of the last recalculation, Immune-Mediated Pancreatitis appears in 364 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 201.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 184 | 201.2 | 201.6 |
| Ipilimumab | 67 | 108.6 | 108.7 |
| Nivolumab | 113 | 96.5 | 96.6 |
| Lenvatinib | 29 | 54.8 | 54.9 |
| Durvalumab | 17 | 50.1 | 50.1 |
| Paclitaxel (Aibumin-Bound) | 46 | 36.5 | 36.5 |
| Carboplatin | 63 | 34.1 | 34.1 |
| Pemetrexed | 12 | 33.1 | 33.1 |
| Paclitaxel | 49 | 32.5 | 32.6 |
| Pemetrexed Disodium | 20 | 31.7 | 31.7 |
| Atezolizumab | 18 | 27.8 | 27.8 |